Kyverna Therapeutics, Inc. KYTX Change in Accrued Liabilities
Change in Accrued Liabilities at other companies
Other financials
Where this comes from
Reported directly by Kyverna Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities.
The official record: Kyverna Therapeutics, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Kyverna Therapeutics, Inc.'s change in accrued liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Kyverna Therapeutics, Inc.'s change in accrued liabilities?
- Kyverna Therapeutics, Inc. (KYTX) reported change in accrued liabilities of -$6.88M in Q1 2026.
- How has Kyverna Therapeutics, Inc.'s change in accrued liabilities changed year-over-year?
- Kyverna Therapeutics, Inc.'s change in accrued liabilities decreased by 281.2% year-over-year, from -$1.8M to -$6.88M.
- What is the long-term trend for Kyverna Therapeutics, Inc.'s change in accrued liabilities?
- Over 2 years (2023 to 2025), Kyverna Therapeutics, Inc.'s change in accrued liabilities has grown at a 90.9% compound annual growth rate (CAGR), from $1.4M to $5.11M.
- What does change in accrued liabilities mean?
- Change in accrued expenses and other current liabilities, reflecting timing differences between expense recognition and cash payment.